| Patent Number |
Title Of Patent |
Date Issued |
| 5403731 |
Process of producing modified superoxide dismutase |
April 4, 1995 |
| A modified superoxide dismutase represented by the formula: ##STR1## (wherein R is as defined below; SOD is a residue of superoxide dismutase) is produced, in a shortened period of reaction with a high and constant modification ratio, by reacting a polymeric carbonyldiimidazole deriv |
| 5371196 |
Process for producing secretory immunoglobulin A preparations |
December 6, 1994 |
| Secretory immunoglobulin A preparations substantially not containing virus are produced by a process wherein secretory immunoglobulin A which might be contaminated with viruses is (1) heated about 60.degree. C. for about 10 hours, or (2) subjected to the reaction with tri-n-butyl phospha |
| 5283239 |
Inhibitor of herpesvirus absorption |
February 1, 1994 |
| LEM which is an aqueous extract of a mycelial culture of Lentinus Edodes and has a sugar composition composed of arabinose, xylose, glucose, mannose, galasctose, fucose and rhamnose, as well as a fraction of LEM which corresponds to molecular weights of 10,000 to 1,000,000 daltons and |
| 5281577 |
Inhibitor of the proliferation of herpes viruses and inhibitor of the recurrence of affections c |
January 25, 1994 |
| An inhibitor of the proliferation of herpesviruses and of the recurrence of affections caused by their latent infection, which is an active material obtained by fractional purification of the aqueous extract from cultured Lentinus edodes mycelia. |
| 5240864 |
Method of assaying or analyzing subtypes of human leukocyte interferons or their antibodies, and |
August 31, 1993 |
| Antiserum which can recognize all subtypes of human leukocyte interferon is prepared from the blood of an animal immunized with partially purified human leukocyte interferon obtained from a culture of human leukocyte stimulated with Sendai virus.The antiserum is added to a column whereon |
| 5173415 |
Process for removal of viruses from solutions of physiologically active substances |
December 22, 1992 |
| A membrane filter of 0.025 to 0.05 .mu. in pore size is treated by passing the solution of a water-soluble high molecular substance such as albumin, dextran, polyvinylpyrrolidone, polysorbate 80, gelatin or the like through the membrane filter. Employing the filter thus treated, the solu |
| 4946785 |
Method of suppressing the thermal degradation of urokinase |
August 7, 1990 |
| The thermal degradation of urokinase in an aqueous solution is suppressed by heating an aqueous solution containing urokinase in the presence of citric acid or a water-soluble salt thereof such as sodium, potassium or lithium citrate at about 60.degree. C. for about 10 hours. |
| 4780209 |
Process for concentrating and separating trypsin inhibitor and kallidinogenase in human urine |
October 25, 1988 |
| Two components, trypsin and kallidinogenase, in human urine are concentrated simultaneously by allowing human urine at neutral pH, collecting bubbles thus formed to obtain the concentrate of the two components, adjusting the concentrate to weak acidity, contacting the acidified conce |
| 4676983 |
Tumor cytostatic-citocidal factor from blood platelets |
June 30, 1987 |
| A tumor cytostatic-cytocidal factor is produced by disrupting platelets, extracting the disrupted platelets with an acidic aqueous solution or an acidic water-organic solvent mixture, and, after gel filtration, if desired, to separate a fraction having an estimated molecular weight of |
| 4665161 |
Process for producing highly purified HCG |
May 12, 1987 |
| Crude HCG is purified by extracting with a neutral or weakly basic aqueous solution containing lower aliphatic alcohol and soluble salt, adding lower aliphatic alcohol to the extracted solution to form precipitates and the precipitates containing high purity of HCG are collected. This |
| 4609546 |
Long-acting composition |
September 2, 1986 |
| A composition wherein a physiologically active polypeptide or a glycoprotein of human origin, for instance, urokinase, kallikrein or leukocyte interferon, is coupled to a polyoxyethylene-polyoxypropylene copolymer. The composition is effective in the human body for a prolonged period |
| 4528186 |
Method of producing human epidermal growth factor |
July 9, 1985 |
| A method for producing a human epidermal growth factor in high yield and high purity by adding particles of an aluminum or magnesium silicate of the formula z.2 (or 6) SiO.sub.2.xH.sub.2 O where Z is Al.sub.2 O.sub.3 or 2MgO and x is the number of water molecules in each molecule of the |
| 4510248 |
Process for concentrating and purifying human urinary kallikrein |
April 9, 1985 |
| Human urinary kallikrein is concentrated and purified by the following procedures; (a) Human urine is contacted with chitosan, a high molecular agglutinant obtained from chitin, at a pH from 4.0 to 7.0, thereby kallikrein is adsorbed on the chitosan and (b) kallikrein is eluted from |
| 4500514 |
Process for preparing a heat-stable aqueous solution of human urine kallikrein and product prepa |
February 19, 1985 |
| Human urine kallikrein dissolved in water is made heat-stable by the addition of a citric acid salt such as sodium citrate, so that an aqueous solution containing the kallikrein and the citric acid salt can be sterilized at 60.degree. to 70.degree. C. |
| 4468344 |
Method of fractional collection of gastric acid secretion inhibiting components |
August 28, 1984 |
| Gastric acid secretion inhibiting substance obtainable from mammalian urine by conventional method is fractionated into the first and second components by gel filtration, adsorption and desorption on ion exchanger or electrophoresis detecting each component by biological test methods. |
